Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)Matthew J. Ellis, Kelly K. Hunt, Vera J. Suman et al.|Journal of Clinical Oncology|2017Cited by 411
Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)Razelle Kurzrock, Benjamin Powers, G. Thomas Budd et al.|Journal for ImmunoTherapy of Cancer|2021Cited by 159
Using novel protein antibodies on tissue microarrays (TMAs) for breast cancer prognosticationG. Thomas Budd, D. Hicks|Journal of Clinical Oncology|2004Cited by 0